News >

Novel Therapies Show Significant Activity in Relapsed/Refractory ALL

Caroline Seymour
Published: Thursday, Dec 05, 2019

Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center

Jae H. Park, MD

Bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and CAR T-cell therapy are all novel treatment modalities that are emerging for patients with relapsed/refractory acute lymphoblastic leukemia (ALL), according to Jae H. Park, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication